REDUCE-IT试验在稳定性冠状动脉疾病患者中的可推广性。 - Suppr

Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease.

作者信息

Picard Fabien, Bhatt Deepak L, Ducrocq Grégory, Elbez Yedid, Ferrari Roberto, Ford Ian, Tardif Jean-Claude, Tendera Michal, Fox Kim M, Steg Philippe Gabriel

出版信息

J Am Coll Cardiol. 2019 Mar 26;73(11):1362-1364. doi: 10.1016/j.jacc.2019.01.016. Epub 2019 Feb 25.

DOI:10.1016/j.jacc.2019.01.016

PMID:30819552

Abstract

摘要

相似文献

Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease.REDUCE-IT试验在稳定性冠状动脉疾病患者中的可推广性。

J Am Coll Cardiol. 2019 Mar 26;73(11):1362-1364. doi: 10.1016/j.jacc.2019.01.016. Epub 2019 Feb 25.

Patient selection for elective revascularization to reduce myocardial infarction and mortality: new lessons from randomized trials, coronary physiology, and statistics.为降低心肌梗死和死亡率而进行择期血运重建的患者选择：来自随机试验、冠状动脉生理学和统计学的新经验教训。

Circ Cardiovasc Imaging. 2015 May;8(5). doi: 10.1161/CIRCIMAGING.114.003099.

The SYNTAX trial: a perspective.SYNTAX 试验：一种观点。

Circ Cardiovasc Interv. 2009 Oct;2(5):463-7. doi: 10.1161/CIRCINTERVENTIONS.109.882670.

PCI or CABG in coronary artery disease?冠心病患者应选择经皮冠状动脉介入治疗（PCI）还是冠状动脉旁路移植术（CABG）？

Lancet. 2009 Apr 4;373(9670):1150-2. doi: 10.1016/S0140-6736(09)60574-2. Epub 2009 Mar 19.

Percutaneous Coronary Intervention of Left Main Disease: Pre- and Post-EXCEL (Evaluation of XIENCE Everolimus Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) and NOBLE (Nordic-Baltic-British Left Main Revascularization Study) Era.左主干疾病的经皮冠状动脉介入治疗：EXCEL（评价依维莫司洗脱支架 XIENCE 与冠状动脉旁路移植术治疗左主干血运重建效果）和 NOBLE（北欧-波罗的海-英国左主干血运重建研究）时代之前和之后。

Circ Cardiovasc Interv. 2017 Jun;10(6). doi: 10.1161/CIRCINTERVENTIONS.117.004792.

Who is eligible for randomized trials? A comparison between the exclusion criteria defined by the ISCHEMIA trial and 3102 real-world patients with stable coronary artery disease undergoing stent implantation in a single cardiology center.谁适合参加随机试验？缺血性心脏病试验定义的排除标准与单中心心脏病科3102例接受支架植入术的稳定冠状动脉疾病真实世界患者的比较。

Trials. 2015 Sep 15;16:411. doi: 10.1186/s13063-015-0934-4.

One year perspective on COURAGE.关于“COURAGE”研究的一年展望。

Catheter Cardiovasc Interv. 2008 Sep 1;72(3):426-429. doi: 10.1002/ccd.21642.

Treatment selection for coronary artery disease: The collision of a belief system with evidence.冠状动脉疾病的治疗选择：一种信念体系与证据的碰撞。

J Thorac Cardiovasc Surg. 2009 May;137(5):1050-3. doi: 10.1016/j.jtcvs.2009.03.043.

[Coronary artery disease: when to withhold a decision and call in the Heart Team? Almost every time].

G Ital Cardiol (Rome). 2018 Nov;19(11 Suppl 2):14S-17S. doi: 10.1714/3019.30157.

The SYNTAX score in practice: an aid for patient selection for complex PCI.SYNTAX评分在实践中的应用：辅助复杂经皮冠状动脉介入治疗患者的选择

Catheter Cardiovasc Interv. 2009 Apr 1;73(5):618-9. doi: 10.1002/ccd.22043.

引用本文的文献

Opportunities and challenges in heart rhythm research: Rationale and development of an electrophysiology collaboratory.心律失常研究中的机遇与挑战：电生理学协作实验室的原理与发展。

Heart Rhythm. 2022 Nov;19(11):1927-1945. doi: 10.1016/j.hrthm.2022.08.004.

Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention.二十碳五烯酸乙酯在心血管疾病一级和二级预防中的全球适用性及成本效益

Front Cardiovasc Med. 2023 Aug 31;10:1220017. doi: 10.3389/fcvm.2023.1220017. eCollection 2023.

Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria.大型糖尿病心血管结局试验中REDUCE-IT纳入标准的可推广性：EMPA-REG结局的事后亚组分析：使用REDUCE-IT标准对EMPA-REG OUTCOME进行分析

Am J Prev Cardiol. 2023 Jun 10;15:100510. doi: 10.1016/j.ajpc.2023.100510. eCollection 2023 Sep.

The Evolving Role of Omega 3 Fatty Acids in Cardiovascular Disease: Is Icosapent Ethyl the Answer?ω-3脂肪酸在心血管疾病中不断演变的作用：二十碳五烯酸乙酯是答案吗？

Heart Int. 2021 Jul 15;15(1):7-13. doi: 10.17925/HI.2021.15.1.7. eCollection 2021.

Contemporary National Patterns of Eligibility and Use of Novel Lipid-Lowering Therapies in the United States.当代美国新型降脂治疗药物的资格认定和使用的国家模式。

J Am Heart Assoc. 2022 Sep 20;11(18):e026075. doi: 10.1161/JAHA.122.026075. Epub 2022 Sep 14.

The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl.用二十碳五烯酸乙酯治疗符合REDUCE-IT标准的美国成年人对人群健康的潜在影响。

Am J Prev Cardiol. 2022 Apr 28;10:100345. doi: 10.1016/j.ajpc.2022.100345. eCollection 2022 Jun.

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.依泽替米贝治疗经皮冠状动脉介入治疗后患者的缺血事件：来自 REDUCE-IT PCI 的见解。

J Am Heart Assoc. 2022 Mar 15;11(6):e022937. doi: 10.1161/JAHA.121.022937. Epub 2022 Mar 9.

Egyptian practical guidance in hypertriglyceridemia management 2021.《2021年埃及高甘油三酯血症管理实用指南》

Egypt Heart J. 2021 Dec 20;73(1):107. doi: 10.1186/s43044-021-00235-9.

Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study.接受他汀类药物一级或二级预防治疗的成年人的甘油三酯水平与动脉粥样硬化性心血管疾病事件和死亡的残余风险：来自 KP REACH 研究的见解。

J Am Heart Assoc. 2021 Oct 19;10(20):e020377. doi: 10.1161/JAHA.120.020377. Epub 2021 Oct 8.

Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.轻中度高甘油三酯血症的心血管疾病风险降低：将ω-3 处方与标准治疗相结合。

Curr Atheroscler Rep. 2021 Mar 31;23(6):27. doi: 10.1007/s11883-021-00919-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献